<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> often have <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, putting them at risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, and are frequently treated with oral anti-hyperglycaemic medications (OAMs) </plain></SENT>
<SENT sid="1" pm="."><plain>This review compares the effects of OAMs on serum <z:chebi fb="23" ids="18059">lipids</z:chebi> [total cholesterol (TC), <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>), <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>), <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (TGs) and free fatty acids (FFAs)] in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: medline was searched for entries indexed from January 1966 to November 2002; search terms included the names of OAMs and serum <z:chebi fb="23" ids="18059">lipids</z:chebi>, limited to English language and human subjects </plain></SENT>
<SENT sid="3" pm="."><plain>We selected clinical studies in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> of OAM monotherapy that included serum <z:chebi fb="23" ids="18059">lipid</z:chebi> data, treated <z:hpo ids='HP_0000001'>all</z:hpo> patients in a treatment group with the same drug, used therapeutic OAM doses not higher than the maximum recommended in the USA, compared therapy with baseline or placebo and specified statistical tests used </plain></SENT>
<SENT sid="4" pm="."><plain>One unblinded investigator selected studies for inclusion </plain></SENT>
<SENT sid="5" pm="."><plain>Data reported include number of patients, study length, OAM dose, serum <z:chebi fb="23" ids="18059">lipid</z:chebi> data at baseline and endpoint, p-values and statistical tests </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Data on the serum <z:chebi fb="23" ids="18059">lipid</z:chebi> effects of sulphonylureas, repaglinide, nateglinide and miglitol were inconclusive </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="2376">Acarbose</z:chebi> increased <z:chebi fb="0" ids="47775">HDL-C</z:chebi> and decreased <z:chebi fb="0" ids="47774">LDL-C</z:chebi> and voglibose reduced TC </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> at higher doses reduced TC; data on its effects on other <z:chebi fb="23" ids="18059">lipids</z:chebi> were inconclusive </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> increased <z:chebi fb="0" ids="47774">LDL-C</z:chebi>, <z:chebi fb="0" ids="47775">HDL-C</z:chebi> and TC and reduced FFAs but had no effect on TGs </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> increased <z:chebi fb="0" ids="47775">HDL-C</z:chebi> and reduced TGs and FFAs but did not affect <z:chebi fb="0" ids="47774">LDL-C</z:chebi> or TC </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="23" ids="18059">Lipid</z:chebi> changes as a result of improved glycaemic control are not uniform findings associated with anti-diabetic therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Only <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="2376">acarbose</z:chebi>, voglibose, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> had significant effects on the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile </plain></SENT>
<SENT sid="13" pm="."><plain>These effects should be considered when selecting OAMs for patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>